Lemtrada is going to be resubmitted to FDA review - drugdiscovery.com
Lemtrada, ths multiple sclerosis drug of Genzyme, a Sanofi company was once rejected by Food and Drug Administration. The resubmission aims to solve problems which were pointed out by FDA previously.
Read More >>
FDA, Lemtrada, multiple sclerosis, sanpfi, Genzyme, resubmission,
April 9, 2014
Lemtrada: would Sanofi invest more into the development
FDA declined one of Sanofi's drug, Lemtrada. This drug is used for treating dementia and multiple sclerosis. According to the news the demnd for multiple sclerosis drugs are growing. However, it is st
Read More >>
developlment, trial, clinical trial
Lilly’s experimental lung cancer drug successful in p...
Sammy Sosa's Skin Lightening
Autologous immune cell therapy tested in liver cancer p...
An experimental breast cancer drug shows potential for ...
Novel brain cancer drug proceeds to the Phase II clinic...
Breakthrough therapy designation for Roche’s lung can...
How Drugs are Developed and Approved
Bayer’s new hypertension drug to be approved by FDA
PAT-SM6 antibody successful in Phase I/IIa clinical tri...
Orphan Drug Designation for Hemophilia B drug ALN-AT3
New erectile dysfunction drug approved in Ireland and...
New drug for treating myeloma approved in Europe
Teva’s drug for treating neutropenia approved in EU
New Pulmonary and Lung Diseases Solution!
Another Sanofi MS drug approved in EU
TERMS & CONDITIONS
All rights reserved drugdiscovery.com 2013